Clinically Isolated Syndrome
Clinically isolated syndrome (CIS) is a condition that serves as an early manifestation of multiple sclerosis (MS). Our company is dedicated to advancing CIS drug and therapy development through our comprehensive services, including therapy development, animal model development, and preclinical research.
Overview of Clinically Isolated Syndrome
Clinically isolated syndrome (CIS) is characterized by a single episode of neurological symptoms that last at least 24 hours. These symptoms may include numbness or tingling, vision problems, muscle weakness, difficulty with coordination, and bladder or bowel dysfunction. CIS can affect various areas of the central nervous system, leading to multifocal or monofocal presentations. The pathogenesis of CIS involves an immune-mediated attack on the myelin sheath, the protective covering of nerve fibers in the central nervous system. This attack leads to inflammation, demyelination, and subsequent neurological symptoms.
Fig.1 Clinically isolated syndromes result in regional brain volume loss. (Hyncicova E., et al., 2018)
Therapy Discovery and Development for Clinically Isolated Syndrome
Clinically isolated syndrome drug and therapy options aim to prevent further relapses and delay the progression of MS. These therapeutics primarily focus on reducing inflammation, modulating the immune response, and promoting neuroprotection. Corticosteroids, such as high-dose intravenous methylprednisolone, are commonly used to alleviate acute symptoms and shorten the duration of relapses. Immunomodulatory therapies, such as β-interferon and glatiramer acetate, have demonstrated efficacy in reducing the conversion of CIS to clinically definite MS and reducing new lesion formation on MRI scans.
At our company, we pride ourselves on our expertise in developing innovative therapies for CIS. If you would like to find out more about the right CIS therapy development solution for you, please click on the link below to learn more.
Our Services
To facilitate the discovery and validation of new therapeutic candidates, we have established robust CIS animal models and in vitro models. Our animal models accurately mimic the pathological features of CIS, enabling us to evaluate the efficacy and safety of potential therapies in a preclinical setting. Additionally, our in vitro models allow for detailed investigations into the mechanisms underlying CIS pathogenesis, providing valuable insights for the development of targeted interventions.
MOG Induced Models
Our company offers expertise in developing CIS related animal model, which involves inducing experimental autoimmune encephalomyelitis (EAE) in animals through immunization with myelin oligodendrocyte glycoprotein (MOG) peptide.
Primary cell cultures derived from CNS tissues, such as the brain and spinal cord, provide a valuable platform for studying CIS. Furthermore, we provide a co-culture system that allows studying cell-cell interactions as well as the complex interactions between different cell types involved in CIS.
The development of cerebral organoids and optic nerve organoids provides a three-dimensional platform to study complex cellular and molecular processes in CIS. By leveraging our expertise in model development, we enable researchers to identify potential therapeutic targets, and develop innovative therapies.
Our state-of-the-art facilities and expert team enable us to conduct in-depth pharmacokinetic and pharmacodynamic studies, safety assessments, and efficacy evaluations. Beyond the aforementioned repertoire of services and models, our expertise extends to crafting personalized solutions and designing disease models that impeccably align with your unique needs. If our comprehensive range of offerings has piqued your interest, we wholeheartedly encourage you to connect with us without any hesitation.
Reference
- Hyncicova E., et al. "Health-related quality of life, neuropsychiatric symptoms and structural brain changes in clinically isolated syndrome." PLoS One 13.7 (2018): e0200254.